PPT-Hematology Mastery in Multiple Myeloma

Part I Smoldering Multiple Myeloma and Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Moderator Sagar Lonial MD Panelists Jonathan Kaufman MD and Ajay Nooka. Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Targeted Cancer Therapies. Dr . Ongóndi. .M. KNH-Dept. Internal Medicine. Hemato. -Oncology. Objectives. Traditional chemotherapy. Targeted chemotherapy. Country status. Challenge !!!. Administer sufficiently high dose of . Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . Program Goals. Defining Multiple Myeloma. Case 1. Diagnostic Criteria. Multiple Myeloma Requiring Therapy. Cytogenetic Risk Features. Case 1 (cont). Newly Diagnosed Multiple Myeloma. NCCN. ®. . Therapy for Transplant-Eligible Patients. Alice J. Cohen, M.D., F.A.C.P.. Newark Beth Israel Medical Center. Associate Clinical Professor of Medicine. Rutgers - New Jersey Medical School. Newark, NJ. Disclosures. None. Scope of the Problem. Maryam-kabootari. MD. Research Institute for Endocrine Sciences . Shahid. . Beheshti. University of Medical Sciences. mordad. 95. Diabetes . insipidus. (DI) belongs to the spectrum of . polyuric. Miss Georgia Stewart . Sheffield Myeloma Research Team. Department of Oncology and Metabolism. Faculty of Medicine Dentistry and Health . University of Sheffield, UK. Most Viruses have a preferential tropism for tumour cells. Plasma cell dyscrasias are diseases characterized by clonal proliferation and accumulation of cells producing monoclonal immunoglobulins. These diseases have not been studied in our region and we don Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.